MAKG—54

MATERNUS-Kliniken-AG

Healthcare Facilities & ServicesVerified

MATERNUS-Kliniken-AG has a basic and diluted share count of 20,970,000, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company reported a last actual EPS of 0.11 EUR and revenue of 123,269,000 EUR, but no industry-specific preferred metrics or cohort medians are available for direct comparison. Geographic and segment revenue concentration data are not disclosed, making it difficult to assess exposure to regional or business-specific risks. Growth trajectory is not quantified in the available data, and no numeric deltas for current or next fiscal years are provided. Risk factors include the inability to assess liquidity risk and the absence of detailed dilution potential or adjustments in valuation data. Recent events, such as filings or transcripts, are not disclosed in the available data.

30-day price · MAKG-0.08 (-7.5%)

Low$0.95High$1.60Close$0.99As of17 May, 00:00 UTC

Profile

CompanyMATERNUS-Kliniken-AG

TickerMAKG.DE

SectorHealthcare

BusinessHealthcare Services & Equipment

Industry groupHealthcare Services & Equipment

IndustryHealthcare Facilities & Services

AI analysis

Business. MATERNUS-Kliniken-AG operates in the healthcare sector, providing medical services and facilities, primarily in Germany.

Classification. The company is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a classification confidence of 0.92.

Key takeaways

MATERNUS-Kliniken-AG operates in the healthcare sector with a focus on medical services and facilities.
The company has no immediate dilution pressure based on current share counts.
Liquidity risk could not be assessed due to missing balance-sheet data.
Revenue and EPS figures are available, but no industry benchmarks are provided for comparison.
No detailed growth projections or risk assessments are disclosed in the available data.
--
## RATIONALES
```json

Financial snapshot

PeriodHA-latest

CurrencyEUR

Revenue—

Gross profit—

Operating income—

Net income—

R&D—

SG&A—

D&A—

SBC—

Operating cash flow—

CapEx—

Free cash flow—

Total assets—

Total liabilities—

Total equity—

Cash & equivalents—

Long-term debt—

Annual history (last 5)

PeriodRevenueOp IncomeNet IncomeFCF

FY-4$114.3M$1.6M-$9.6M$1.2M

FY-3$111.4M$3.8M-$2.5M$6.7M

FY-2$106.7M-$9.4M-$14.1M-$5.1M

FY-1$102.3M-$5.3M-$14.3M-$8.5M

FY0$114.0M-$2.3M-$13.2M-$1.8M

PeriodGross %Op %Net %FCF %

FY-4————

FY-3————

FY-2————

FY-1————

FY0————

PeriodAssetsEquityCashDebt

FY-4$178.6M-$25.4M——

FY-3$165.4M-$27.8M——

FY-2$153.4M-$39.3M——

FY-1$154.4M-$53.8M——

FY0$139.9M-$66.8M——

PeriodOCFCapExFCFSBC

FY-4$12.2M-$736.0k$1.2M—

FY-3$17.2M-$1.9M$6.7M—

FY-2$4.3M-$2.0M-$5.1M—

FY-1$2.5M-$4.0M-$8.5M—

FY0$15.1M-$1.2M-$1.8M—

Quarterly history (last 4)

PeriodRevenueOp IncomeNet IncomeFCF

FQ-7————

FQ-6———-$3.1M

FQ-5————

FQ-4————

FQ-3————

FQ-2————

FQ-1————

FQ0————

PeriodGross %Op %Net %FCF %

FQ-7————

FQ-6————

FQ-5————

FQ-4————

FQ-3————

FQ-2————

FQ-1————

FQ0————

PeriodAssetsEquityCashDebt

FQ-7————

FQ-6$154.4M-$53.8M$551.0k—

FQ-5————

FQ-4————

FQ-3————

FQ-2————

FQ-1————

FQ0————

PeriodOCFCapExFCFSBC

FQ-7————

FQ-6$2.5M-$4.0M-$3.1M—

FQ-5————

FQ-4————

FQ-3————

FQ-2————

FQ-1————

FQ0————

Valuation

Market price—

Market cap—

Enterprise value—

P/E—

Reported non-GAAP P/E—

EV/Revenue—

EV/Op income—

EV/OCF—

P/B—

P/Tangible book—

Tangible book—

Net cash—

Current ratio—

Debt/Equity—

ROA—

ROE—

Cash conversion—

CapEx/Revenue—

SBC/Revenue—

Asset intensity—

Dilution ratio0.0%

Risk assessment

Dilution riskLow

Liquidity riskUnknown

Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).

Industry benchmarks

Activity: Biotechnology · cohort 117 companies

MetricMAKGActivity

Op margin—5.6% medp25 -4.2% · p75 12.6%

Net margin—2.8% medp25 -3.4% · p75 8.8%

Gross margin—36.5% medp25 23.7% · p75 65.2%

CapEx / revenue—-4.9% medp25 -11.5% · p75 -2.0%

Debt / equity—69.3% medp25 7.9% · p75 120.9%

Observations

IR observations

Last actual EPS0.11 EUR

Last actual revenue123,269,000 EUR

Source data

Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.

Company fundamentalsperiod FQ-7 · history via verified-market-data

no public URL

2026-05-08 02:31 UTC#d84ef562

Source: analysis-pipeline (hybrid)Generated: 2026-05-28 12:04 UTCJob: 4a24985c